Literature DB >> 30879275

Dopaminergic Effects of Major Bath Salt Constituents 3,4-Methylenedioxypyrovalerone (MDPV), Mephedrone, and Methylone Are Enhanced Following Co-exposure.

Serena A Allen1, Lily H Tran1, Hannah V Oakes1, Russell W Brown2, Brooks B Pond3.   

Abstract

Designer drug mixtures popularized as "bath salts" often contain the synthetic cathinones 3,4 methylenedioxypyrovalerone (MDPV), mephedrone, and methylone in various combinations. However, most preclinical investigations have only assessed the effects of individual bath salt constituents, and little is known about whether co-exposure to MDPV, mephedrone, and methylone produces significant neuropharmacological interactions. This study evaluated and compared how MDPV, mephedrone, and methylone influence discrete brain tissue dopamine (DA) levels and motor stimulant responses in mice when administered alone and as a ternary mixture. Male adolescent Swiss-Webster mice received intraperitoneal injections of saline or 1 or 10 mg/kg doses of MDPV, mephedrone, or methylone, or a cocktail of all three cathinones at doses of 1, 3.3, or 10 mg/kg each. The effect of each treatment on DA and DA metabolite levels in mesolimbic and nigrostriatal brain tissue was quantified 15 min after a single exposure using HPLC-ECD. Additionally, locomotor activity was recorded in mice after acute (day 1) and chronic intermittent (day 7) dosing. MDPV, mephedrone, and methylone produced dose-related increases in mesolimbic and nigrostriatal DA levels that were significantly enhanced following their co-administration. In addition, mice treated with the cathinone cocktail displayed decreased locomotor activity on day 1 that was exacerbated by day 7 and not observed with any of the drugs alone. Our findings demonstrate a significant enhanced effect of MDPV, mephedrone, and methylone on both DA, and these effects on DA result in significant alterations in locomotor activity.

Entities:  

Keywords:  Bath salts; Locomotor activity; Mephedrone; Methylenedioxypyrovalerone; Methylone; Synthetic cathinones

Mesh:

Substances:

Year:  2019        PMID: 30879275     DOI: 10.1007/s12640-019-00020-2

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  4 in total

1.  The clinical challenges of synthetic cathinones.

Authors:  Fabrizio Schifano; Flavia Napoletano; Davide Arillotta; Caroline Zangani; Liam Gilgar; Amira Guirguis; John Martin Corkery; Alessandro Vento
Journal:  Br J Clin Pharmacol       Date:  2020-02-03       Impact factor: 4.335

2.  Pharmacokinetics of Synthetic Cathinones Found in Bath Salts in Mouse Brain and Plasma Using High-Pressure Liquid Chromatography-Tandem Mass Spectrometry.

Authors:  Courtney Gearlds; Jessica Brooke Bouldin; Mariah McKinney; Shannon Schreiner; Stacy D Brown; Brooks B Pond
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-08-24       Impact factor: 2.441

3.  3,4-Methylenedioxypyrovalerone (MDPV) Sensing Based on Electropolymerized Molecularly Imprinted Polymers on Silver Nanoparticles and Carboxylated Multi-Walled Carbon Nanotubes.

Authors:  Rosa A S Couto; Constantino Coelho; Bassim Mounssef; Sara F de A Morais; Camila D Lima; Wallans T P Dos Santos; Félix Carvalho; Cecília M P Rodrigues; Ataualpa A C Braga; Luís Moreira Gonçalves; M Beatriz Quinaz
Journal:  Nanomaterials (Basel)       Date:  2021-02-01       Impact factor: 5.076

4.  Behavioral Effects of 4-CMC and 4-MeO-PVP in DBA/2J Mice After Acute and Intermittent Administration and Following Withdrawal from Intermittent 14-Day Treatment.

Authors:  Jakub Wojcieszak; Katarzyna Kuczyńska; Jolanta B Zawilska
Journal:  Neurotox Res       Date:  2021-01-11       Impact factor: 3.978

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.